3 Reasons MED is Risky and 1 Stock to Buy Instead

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

MED Cover Image

Since January 2026, Medifast has been in a holding pattern, posting a small return of 3.3% while floating around $11.05.

Is now the time to buy Medifast, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it’s free.

Why Do We Think Medifast Will Underperform?

We’re cautious about Medifast. Here are three reasons why there are better opportunities than MED, plus one stock we’d rather own.

1. Revenue Spiraling Downwards

Examining a company’s long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Medifast’s demand was weak over the last three years as its sales fell at a 39.1% annual rate. This was below our standards and is a sign of poor business quality.

Medifast Quarterly Revenue

2. Fewer Distribution Channels Limit Its Ceiling

With $346.1 million in revenue over the past 12 months, Medifast is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.

3. EPS Trending Down

We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.

Sadly for Medifast, its EPS and revenue declined by 28.9% and 39.1% annually over the last three years. We tend to steer our readers away from companies with falling revenue and EPS, where diminishing earnings could imply changing secular trends and preferences. If the tide turns unexpectedly, Medifast’s low margin of safety could leave its stock price susceptible to large downswings.

Medifast Trailing 12-Month EPS (GAAP)

Final Judgment

We see the value of companies helping consumers, but in the case of Medifast, we’re out. That said, the stock currently trades at $11.05 per share (or a forward price-to-sales ratio of 0.4×). The market typically values companies like Medifast based on their anticipated profits for the next 12 months, but it expects the business to lose money. We also think the upside isn’t great compared to the potential downside here - there are more exciting stocks to buy. We’d recommend looking at a fast-growing restaurant franchise with an A+ ranch dressing sauce.

High-Quality Stocks for All Market Conditions

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.42
-3.56 (-1.45%)
AAPL  313.69
+3.03 (0.98%)
AMD  514.18
-1.93 (-0.37%)
BAC  58.58
-1.28 (-2.15%)
GOOG  357.89
-5.73 (-1.58%)
META  605.32
-10.26 (-1.67%)
MSFT  383.54
-5.30 (-1.36%)
NVDA  202.73
+5.80 (2.95%)
ORCL  138.54
-3.06 (-2.16%)
TSLA  394.51
-8.39 (-2.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.